https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiscovery_and_development_of_angiotensin_receptor_blockers%2F43%2FenTranslations:Discovery and development of angiotensin receptor blockers/43/en - Revision history2026-08-15T02:54:43ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_angiotensin_receptor_blockers/43/en&diff=131500&oldid=prevFuzzyBot: Importing a new version from external source2024-03-28T01:25:31Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>==ARBs under development==<br />
[[File:Pratosartan.svg|right|thumb|[[Pratosartan]] structure.]]<br />
Several new nonpeptide ARBs are undergoing [[clinical trials]] or are at pre-clinical stages of development. Among these are [[embusartan]] (BAY 10-6734 or BAY 10-6734), KRH-594, [[fonsartan]] (HR 720) and [[pratosartan]] (KT3-671). Pratosartan, for example, has a novel structure: a seven-membered ring that bears an [[Ketone|oxo]] moiety (C=O) fused to the imidazole ring (figure 4), and its affinity for the AT<sub>1</sub> receptor is about 7 times higher than losartan's. The purpose of the [[Ketone|oxo]] group is similar to that of the carboxylic acid groups on other ARBs.<br /><br />
Other attributes of ARBs are also under investigation, such as the positive effects of telmisartan on [[lipid metabolism|lipid]] and [[glucose metabolism]] and losartan's effects of lowering [[uric acid]] levels. Such effects might lead to new indications for these drugs but further research is needed.</div>FuzzyBot